How Much Do GLP-1 Medications Cost in 2026? Complete Price Breakdown

Quick Answer:

Brand-name GLP-1 list prices range from $935 to $1,637/month at retail pharmacies, but almost nobody should pay sticker price in 2026
Eli Lilly's LillyDirect program offers Zepbound vials at $299-$449/month, and Novo Nordisk sells the new Wegovy pill starting at $149/month for lower doses
Medicare's GLP-1 Bridge program launches July 2026 with a $50/month copay for eligible beneficiaries -- the biggest federal price intervention yet
Compounded semaglutide from telehealth platforms runs $119-$299/month, though FDA regulatory tightening in 2026 has narrowed availability

Affiliate disclosure: This article contains affiliate links. We may earn a commission if you make a purchase through our links, at no extra cost to you.

The question everyone asks about GLP-1 medications is the same one that stops most people from starting them: how much does this actually cost?

Fair question. The list prices are brutal. A month of Wegovy injections carries a sticker price of $1,637. Ozempic sits at $1,363. Even the "affordable" option, Rybelsus, lists at nearly $1,000.

But list price and what you actually pay are two very different numbers in 2026. Between manufacturer direct programs, the new Medicare GLP-1 Bridge, employer insurance expansion, telehealth platforms, and the oral Wegovy pill launch, the real cost landscape has shifted dramatically since 2024.

We broke down every GLP-1 medication on the market, every pricing pathway, and every legitimate discount program. This is the complete picture.

Every GLP-1 Medication: Full Retail List Prices (March 2026)

First, the baseline. These are the manufacturer list prices you would see at a retail pharmacy without any insurance or discount program applied:

Medication	Manufacturer	Type	Monthly List Price	FDA Approved For
Wegovy (semaglutide 2.4 mg)	Novo Nordisk	Injection	$1,637	Chronic weight management
Wegovy Pill (semaglutide 25 mg)	Novo Nordisk	Oral tablet	$1,349	Chronic weight management
Ozempic (semaglutide)	Novo Nordisk	Injection	$1,363	Type 2 diabetes
Saxenda (liraglutide)	Novo Nordisk	Injection	$1,349	Chronic weight management
Mounjaro (tirzepatide)	Eli Lilly	Injection	$1,327	Type 2 diabetes
Zepbound (tirzepatide)	Eli Lilly	Injection	$1,059	Chronic weight management
Rybelsus (semaglutide)	Novo Nordisk	Oral tablet	$998	Type 2 diabetes

Those numbers represent the ceiling. Almost every patient in 2026 has at least one pathway to pay significantly less. The floor depends on your insurance status, income, and which medication you need.

Let us walk through every pricing tier.

Tier 1: Insurance Coverage -- What Most Americans Actually Pay

Commercial Insurance (Employer Plans)

If you get health insurance through your employer, your GLP-1 costs depend entirely on whether your plan covers the specific medication and indication.

Here is where things stand in 2026:

48% of employers now cover GLP-1 medications for weight loss, up from roughly 25% in 2023 (Mercer, 2026)
55% of employers cover GLP-1s for type 2 diabetes management
64% of employers with 20,000+ employees cover GLP-1s for weight loss -- large companies are far more likely to provide coverage
89% of employers currently covering GLP-1s plan to maintain that coverage over the next one to two years (WorldatWork, 2025)

If your plan does cover your medication, typical out-of-pocket costs look like this:

Coverage Level	Monthly Copay Range	Annual Out-of-Pocket
Preferred formulary tier	$25-$75	$300-$900
Non-preferred specialty tier	$100-$250	$1,200-$3,000
Specialty with prior authorization	$150-$350	$1,800-$4,200
High-deductible plan (pre-deductible)	Full price until deductible met	$3,000-$7,000+

The catch: more than 60% of employers that cover GLP-1s for weight loss have restrictions beyond basic prior authorization. Common requirements include BMI thresholds (typically 30+ or 27+ with comorbidities), documentation of failed lifestyle interventions, mandatory nutritional counseling participation, and step therapy requirements.

What "Covered" Actually Means

Getting insurance to pay is not automatic. Most plans require:

Prior authorization -- your doctor submits clinical documentation proving medical necessity
Step therapy -- you may need to try and fail cheaper medications first (metformin for diabetes, phentermine for weight loss)
Ongoing documentation -- some plans require weight loss progress reports every 3-6 months to continue covering the medication
Specific diagnoses -- a plan might cover Mounjaro for diabetes but deny it for weight loss, or cover Wegovy for obesity but not for patients with a BMI under 30

For a deeper breakdown of insurance navigation tactics, see our GLP-1 savings programs guide.

Medicare Coverage: The 2026 Game-Changer

The biggest pricing development of 2026 is the Medicare GLP-1 Bridge program, launching July 2026 through the Centers for Medicare & Medicaid Services (CMS).

How it works:

Participating manufacturers (Novo Nordisk and Eli Lilly both signed on) provide GLP-1 drugs at a net price of $245 per monthly supply to pharmacies
Eligible Medicare Part D beneficiaries pay a flat $50/month copay
The program covers injectable GLP-1s approved for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity
This is a CMS payment demonstration, not permanent legislation -- but it signals a major shift in federal policy

Before this program, Medicare Part D did not cover weight loss medications at all. Beneficiaries who wanted Wegovy or Zepbound for obesity had to pay full retail or find alternative pathways. The $50/month copay represents a 97% reduction from list price.

Medicaid Coverage

Medicaid coverage for GLP-1s varies dramatically by state. As of March 2026:

Most state Medicaid programs cover GLP-1s for type 2 diabetes
Only a handful of states cover GLP-1s specifically for weight loss
Prior authorization requirements are nearly universal
Some states have implemented preferred drug lists that favor older, cheaper GLP-1s (like liraglutide) over newer options

If you are on Medicaid and need a GLP-1, start by checking your state's preferred drug list and working with your provider on prior authorization documentation.

Tier 2: Manufacturer Direct Programs

Both Novo Nordisk and Eli Lilly have expanded their direct-to-consumer pricing programs significantly in 2026. These programs bypass insurance entirely and offer fixed monthly pricing.

Novo Nordisk: NovoCare Pharmacy

Novo Nordisk launched NovoCare Pharmacy to sell its GLP-1 medications directly to patients at reduced prices:

Medication	Monthly Direct Price	Notes
Ozempic 0.25-1 mg	$349/month	Self-pay, no insurance needed
Ozempic 2 mg	$499/month	Highest dose tier
Wegovy injection	$349/month	Maintenance dose pricing
Wegovy Pill (1.5-4 mg)	$149/month	Introductory pricing through August 2026
Wegovy Pill (9-25 mg)	$299/month	Higher maintenance doses
Rybelsus	$349/month	All doses

The oral Wegovy pill deserves special attention. Launched in early 2026, it is the first pill form of semaglutide approved for weight loss. The $149/month introductory price for starter doses makes it one of the most accessible brand-name GLP-1 options on the market right now.

For details on the Wegovy pill and other oral options, read our oral GLP-1 pills guide.

Eli Lilly: LillyDirect

Eli Lilly's LillyDirect platform has been aggressive on pricing, particularly for Zepbound single-dose vials:

Medication/Dose	Monthly LillyDirect Price	Notes
Zepbound 2.5 mg vial	$299/month	Starting dose
Zepbound 5 mg vial	$399/month	Titration dose
Zepbound 7.5-15 mg vial	$449/month	Maintenance doses (must refill within 45 days)
Mounjaro	Similar pricing tiers	Through LillyDirect with valid Rx

Important fine print on Zepbound vials: The $449/month price for 7.5 mg, 10 mg, 12.5 mg, and 15 mg vials only applies on first fill and when refilled within 45 days. Miss that window and the 12.5 mg vial jumps to $849 and the 15 mg vial to $1,049. Set a calendar reminder.

A one-month supply through LillyDirect means 4 single-dose vials for a 28-day period. You self-inject from the vial rather than using a pre-filled pen, which is how Lilly keeps costs lower.

For a complete breakdown of Zepbound pricing, dosing, and results, check out our Zepbound complete guide.

Manufacturer Savings Cards and Coupons

Both manufacturers offer additional savings programs for commercially insured patients:

Wegovy Savings Card: Eligible commercially insured patients may pay as little as $0-$25/month, with maximum savings limits per fill
Ozempic Savings Card: Up to $150 off per prescription for commercially insured patients
Mounjaro Savings Card: Eligible patients may pay as little as $25/month for up to 24 months
Rybelsus Savings Card: As low as $10 for a 1-3 month supply for qualifying insured patients

These cards do not work with Medicare, Medicaid, or other government insurance programs. They are designed for commercially insured patients whose plans cover the medication but have high copays.

Tier 3: TrumpRx and Government Programs

The TrumpRx Portal

Launched February 6, 2026, TrumpRx (trumprx.gov) is a government portal connecting patients to manufacturer discount programs and partner pharmacies. It is not a pharmacy itself -- think of it as a federally backed coupon aggregator.

Current TrumpRx pricing for GLP-1s:

Ozempic and Wegovy: Starting at approximately $199/month through GoodRx partnerships
Zepbound and Mounjaro: $245-$350/month depending on dose
Prices fluctuate based on which manufacturer deals are active

Who it helps most: Uninsured patients or those with insurance plans that do not cover GLP-1s. The portal aggregates existing discount programs into one place, which saves time but does not always deliver lower prices than going directly to manufacturer programs.

For a comprehensive ranking of every discount pathway, see our GLP-1 savings programs guide.

State-Level Programs

Several states have launched their own GLP-1 access initiatives in 2025-2026:

California: Expanded Medi-Cal coverage for GLP-1s for weight management with prior authorization
New York: State employee health plans now cover all FDA-approved GLP-1s for obesity
Colorado: Passed legislation requiring commercial insurers to cover at least one GLP-1 for weight management

Check your state's insurance department website for the most current coverage mandates.

Tier 4: Compounded Semaglutide and Telehealth

Compounded semaglutide has been the budget option since 2023. But 2026 brought significant changes to this market.

Current Compounded Semaglutide Pricing

Provider	Monthly Cost	Includes	Pharmacy Type
GobyMeds	$119/month	3-month starter bundle	503B
MyStart Health	$149/month	3-month plan rate	503B
Hims	$199/month	Medication + provider visits	503B
Ro	$199/month	Medication + ongoing support	503B
SkinnyRx	$199/month	Injectable or sublingual	503B
Henry Meds	$249/month	Medication + monthly check-ins	503A
Found	$299/month	Medication + coaching + app	503B

The Regulatory Shift

Here is the critical context for 2026: after the FDA ended the national semaglutide shortage declaration, the legal basis for many compounding pharmacies to produce semaglutide tightened. Only patients with documented medical needs that cannot be met by commercially available products are now eligible for compounded versions.

What this means practically:

Fewer providers are offering compounded semaglutide compared to 2024-2025
Prices have risen at many telehealth platforms due to reduced supply
Quality screening matters more than ever -- look for PCAB-accredited pharmacies or 503B outsourcing facilities that undergo FDA inspections
A 2024 FDA investigation found that 12 out of 30 tested compounded semaglutide products failed potency testing, delivering between 60% and 140% of the labeled dose

If you are considering compounded options, our cheapest GLP-1 without insurance guide breaks down which providers are legitimate.

Compounded Tirzepatide

Compounded tirzepatide (the active ingredient in Mounjaro and Zepbound) is also available from some telehealth platforms:

Typical pricing: $249-$399/month
Less widely available than compounded semaglutide
Same regulatory tightening applies
Fewer long-term safety studies on compounded formulations compared to semaglutide

Tier 5: What Is Coming Next -- Pipeline Medications

Retatrutide: The Triple Agonist

Retatrutide is the GLP-1 medication generating the most anticipation. It targets three hormones (GLP-1, GIP, and glucagon) rather than two like tirzepatide or one like semaglutide.

Current status (March 2026):

Phase 3 clinical trials (TRIUMPH program) with primary completion dates between January-May 2026
NDA submission to FDA expected late 2026
Earliest plausible FDA approval: mid-2027
Projected commercial launch: early 2028
Estimated pricing: $1,000-$1,500/month based on tirzepatide's pricing trajectory

In Phase 2 trials, retatrutide produced average weight loss of 24.2% of body weight at the highest dose over 48 weeks -- substantially more than either semaglutide or tirzepatide showed at equivalent trial stages.

You cannot buy retatrutide legally in the United States outside of clinical trials right now. Any website claiming to sell it is selling research chemicals not intended for human use.

For a comparison of which GLP-1 fits different needs, see our best GLP-1 for weight loss vs. diabetes guide.

Orforglipron: The Non-Peptide Pill

Eli Lilly's orforglipron is another pipeline medication to watch. Unlike semaglutide (which is a peptide that degrades in the stomach), orforglipron is a small molecule that can be taken as a simple daily pill without the food-timing restrictions of Rybelsus.

Currently in Phase 3 trials
Potential FDA approval: late 2026 or 2027
Expected pricing: competitive with or below current oral semaglutide options
Could fundamentally change the oral GLP-1 market

Read more about what is coming in our oral GLP-1 pills guide.

Side-by-Side: What You Will Actually Pay in Every Scenario

Here is the practical breakdown. Find your situation and see what a month of GLP-1 therapy realistically costs:

Scenario 1: Good Commercial Insurance

Medication	Likely Monthly Cost	How
Ozempic	$25-$75	Preferred tier + savings card
Wegovy	$0-$25	With manufacturer savings card
Mounjaro	$25-$50	With savings card
Zepbound	$25-$75	Preferred formulary

Scenario 2: Insurance That Does Not Cover GLP-1s for Weight Loss

Medication	Likely Monthly Cost	How
Zepbound vial	$299-$449	LillyDirect self-pay
Wegovy Pill	$149-$299	NovoCare direct
Ozempic	$349	NovoCare Pharmacy
Compounded semaglutide	$119-$299	Telehealth platform

Scenario 3: No Insurance at All

Medication	Likely Monthly Cost	How
Compounded semaglutide	$119-$199	Budget telehealth
Wegovy Pill (starter)	$149	Introductory offer
Zepbound vial (starter)	$299	LillyDirect
TrumpRx portal	$199-$350	Government pricing

Scenario 4: Medicare (Starting July 2026)

Medication	Likely Monthly Cost	How
Eligible GLP-1s	$50/month	Medicare GLP-1 Bridge program

GLP-1 Price Trends: Where Costs Are Heading

Understanding the trajectory matters as much as today's numbers. GLP-1 pricing is moving in a clear direction, and it is mostly good news for patients.

Prices Have Already Dropped Significantly

Compare March 2026 to March 2024:

Zepbound: Lilly introduced vials at $399-$549/month in late 2024, then cut them to $299-$449/month in early 2026 -- a 15-25% reduction in just over a year
Wegovy: The launch of the oral pill at $149-$299/month created a lower-cost entry point that did not exist 18 months ago
Compounded semaglutide: Average prices have actually risen slightly (from $149 to $199/month at major platforms) due to regulatory tightening, but overall access through legitimate channels has expanded
Medicare: Coverage went from zero to $50/month in 2026 -- an infinite percentage improvement

What Is Driving Prices Down

Three structural forces are pushing GLP-1 costs lower, and none of them are going away:

Competition between manufacturers: Eli Lilly and Novo Nordisk are in a direct price war. Every time one lowers prices, the other responds. LillyDirect's vial pricing forced Novo Nordisk to launch competitive direct pricing through NovoCare. This dynamic will only intensify as pipeline drugs like retatrutide and orforglipron reach market.
Political pressure: GLP-1 affordability has become a bipartisan issue. The TrumpRx portal, the Medicare GLP-1 Bridge, and state-level coverage mandates all reflect political will to address pricing. With 40% of American adults qualifying for GLP-1 therapy based on BMI criteria alone, this pressure will not ease.
Patent expirations: Semaglutide's core patents begin expiring in 2031-2032. Generic semaglutide could enter the market by 2033, which would likely cut prices by 70-80% based on historical patterns with other biologics. That is still years away, but it sets a ceiling on how long current pricing can hold.

When Generic GLP-1s Will Arrive

Do not hold your breath for generics. The timeline:

Semaglutide patents: Core compound patents expire 2031-2032, but formulation and delivery device patents extend protection further
Tirzepatide patents: Even newer, with core patents extending into the mid-2030s
Biosimilar complexity: GLP-1s are peptide-based biologics, not simple chemical compounds. Biosimilar (generic equivalent) development requires extensive clinical testing, which adds 3-5 years beyond patent expiration
Realistic generic availability: 2034-2036 for semaglutide biosimilars, later for tirzepatide

In the meantime, the manufacturer direct programs, Medicare expansion, and telehealth competition are doing more to reduce out-of-pocket costs than generics would have anyway at this point.

How GLP-1 Costs Compare to Alternatives

GLP-1 medications are expensive. But what is the alternative? Here is how the costs stack up against other weight management and diabetes interventions:

Intervention	Monthly Cost	Average Weight Loss	Sustained at 2 Years?
GLP-1 medication (with discounts)	$150-$450	15-24% body weight	Yes, while on medication
Bariatric surgery (amortized over 5 years)	$350-$600	25-35% body weight	Yes, mostly permanent
Medical weight management program	$200-$500	5-10% body weight	Often regained
Commercial diet program (Noom, WW)	$30-$60	3-5% body weight	Usually regained
Gym membership + trainer	$100-$300	2-5% body weight	Varies widely
No intervention (obesity-related healthcare costs)	$400-$600	N/A	N/A

That last line is the one most people miss. The average obese adult in America spends $4,900-$7,200 more per year on healthcare than a healthy-weight adult (Milken Institute, 2024). Type 2 diabetes adds another $9,600 annually in direct medical costs (ADA, 2023). A $300/month GLP-1 that prevents or reverses these conditions can actually save money over a 5-10 year horizon.

This does not mean GLP-1s are affordable for everyone. They are not. But the framing of "expensive weight loss drug" misses the broader economic picture.

Hidden Costs Most Guides Do Not Mention

The monthly medication price is not the whole picture. Budget for these too:

Provider Visits and Monitoring

Initial consultation: $75-$250 (telehealth) or $150-$400 (in-person)
Follow-up visits: $50-$150 every 1-3 months
Lab work: $100-$300 for baseline panels (metabolic, thyroid, lipids), then $50-$150 for periodic monitoring
Many telehealth platforms bundle consultations into their monthly price, but not all include lab work

Injection Supplies (for Vials)

If you use Zepbound single-dose vials through LillyDirect rather than pre-filled pens:

Syringes: $10-$20 per month
Alcohol swabs: $5-$10 per month
Sharps container: $5-$15 (one-time, lasts months)

Pre-filled pens (standard Ozempic, Wegovy, Mounjaro) include everything you need. No extra supplies required.

The Real Annual Cost

When you factor in everything -- medication, provider visits, labs, and supplies -- here is what a full year on GLP-1 therapy actually costs:

Pathway	Monthly All-In	Annual All-In
Good insurance + savings card	$50-$125	$600-$1,500
LillyDirect Zepbound vials	$350-$550	$4,200-$6,600
NovoCare Wegovy Pill	$200-$400	$2,400-$4,800
Compounded semaglutide	$170-$350	$2,040-$4,200
Medicare GLP-1 Bridge	$75-$125	$900-$1,500
Full retail, no discounts	$1,000-$1,700	$12,000-$20,400

How to Get the Lowest Price: Step-by-Step

Step 1: Check Your Insurance First

Even if you think your plan does not cover GLP-1s, verify. Call the number on the back of your insurance card and ask specifically:

"Does my plan cover [specific medication name] for [your diagnosis]?"
"What tier is it on?"
"What is the prior authorization process?"
"Are there step therapy requirements?"

Step 2: Apply for Manufacturer Programs

If your insurance covers the medication but the copay is high, apply for savings cards:

Wegovy: wegovy.com/savings
Ozempic: ozempic.com/savings
Mounjaro: mounjaro.com/savings
Zepbound: zepbound.lilly.com/savings

Step 3: Consider Direct Purchase Programs

If insurance does not cover your medication at all:

Zepbound vials via LillyDirect ($299-$449/month)
Wegovy Pill via NovoCare ($149-$299/month)
Ozempic via NovoCare ($349/month)

Step 4: Explore Compounded Options

If brand-name direct programs are still too expensive:

Research PCAB-accredited telehealth platforms
Verify the compounding pharmacy is a 503B outsourcing facility
Ask for a Certificate of Analysis for your batch
Budget $119-$299/month

Step 5: Check Government Programs

Visit trumprx.gov for aggregated discount programs
If you are on Medicare, ask about the GLP-1 Bridge program launching July 2026
Check your state's Medicaid formulary if applicable

Frequently Asked Questions

What is the cheapest GLP-1 medication available in 2026?

The cheapest brand-name option is the oral Wegovy pill at $149/month through NovoCare for starter doses (1.5 mg and 4 mg), though this introductory pricing ends August 2026. For the absolute lowest price, compounded semaglutide from telehealth platforms starts at $119/month through providers like GobyMeds, though availability has tightened after the FDA ended the semaglutide shortage declaration.

Will Medicare cover GLP-1 drugs for weight loss in 2026?

Yes, starting July 2026. The Medicare GLP-1 Bridge program is a CMS payment demonstration that allows eligible Part D beneficiaries to access GLP-1 medications approved for chronic weight management at a $50/month copay. Participating manufacturers provide the drugs at a net price of $245 per monthly supply. Eligibility requires a BMI of 30+ or 27+ with at least one weight-related comorbidity.

Is compounded semaglutide still legal in 2026?

Compounded semaglutide is still legal but under stricter conditions. After the FDA ended the national semaglutide shortage in 2026, compounding pharmacies can only produce semaglutide for patients with documented medical needs that cannot be met by commercially available products. Fewer providers are offering it compared to 2024-2025, and patients should verify that their pharmacy holds PCAB accreditation or operates as a 503B outsourcing facility.

How much does Zepbound cost through LillyDirect without insurance?

Zepbound single-dose vials through LillyDirect cost $299/month for the 2.5 mg starting dose, $399/month for 5 mg, and $449/month for maintenance doses (7.5-15 mg). The maintenance dose price only applies on first fill and when refilling within 45 days of the previous delivery. Missing the 45-day window can increase costs to $849-$1,049/month for higher doses. A one-month supply equals 4 vials for a 28-day period.

When will retatrutide be available and how much will it cost?

Retatrutide is currently in Phase 3 clinical trials with primary completion expected in early-to-mid 2026. An NDA submission to the FDA is expected in late 2026, with the earliest plausible approval in mid-2027 and commercial launch in early 2028. Based on tirzepatide's pricing, analysts estimate retatrutide will cost $1,000-$1,500/month at list price. It produced 24.2% average body weight loss at the highest dose in Phase 2 trials.